Form 4: Sensei Biotherapeutics Director Thomas G. Ricks Acquires Stock Options

Director Thomas G. Ricks of Sensei Biotherapeutics acquired stock options exercisable for 19,000 shares of common stock.

Summary

• Thomas G. Ricks, a director of Sensei Biotherapeutics, Inc. (SNSE), filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on June 11, 2024, where Ricks acquired stock options.
• These options grant the right to buy 19,000 shares of Sensei Biotherapeutics common stock at an exercise price of $0.709 per share.
• The options vest in 12 equal monthly installments over one year, fully vesting on June 11, 2025, subject to continuous service.
• The options will be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.
• Following the reported transaction, Ricks directly owns derivative securities for 19,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director. The positive aspect is the director's increased stake in the company, but it's a routine event.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation in the biopharmaceutical industry.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in the biotechnology industry.
• The vesting schedule of 12 months is also typical, aligning the director's interests with the company's short-term performance.
• The exercise price of $0.709 is relevant to the current market price of SNSE shares, and the potential for future gains depends on the company's performance and stock price appreciation.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment, as it signals confidence in the company's future.

Key Dates

Keywords

Form 4, Sensei Biotherapeutics, Stock Options, Director, Beneficial Ownership, SNSE